To investigate whether any point mutations at the poly (A) site could explain the continuation of the SLC45A3 transcript, we sequenced the last exon of the SLC45A3 gene in LNCaP (a prostate cancer cell line responsive to androgen), PC3 (a prostate cancer cell line unresponsive to androgen), RWPE-1 (a benign prostate epithelial cell line), and a normal placenta control. The gene discussed is SLC45A3; the disease is prostate carcinoma.